ID: 417 Human T cell receptor transgenic CD8+ T cells specifically kill HLA-A*0201/ CHM1+ Ewing sarcoma lines in vitro and in a preclinical mouse model ID: 516 Thiel, U. (München) The effects of sensorimotor training and whole body vibration on patients suffering from chemotherapy-induced peripheral neuropathy Streckmann, F. (Köln) ID: 493 Sarcoma research by 3D cell culture | Becerikli, M. (Bochum) ID: 521 ID: 555 Defektdeckungen am Capillitium: Therapieoptionen und perioperatives Management | Kolbenschlag, J. (Bochum) MeMa pilot study – effects of an exercise program for patients with metastatic breast cancer | Wirtz, P. (Köln) ID: 529 ID: 556 Freie Lappenplastiken nach Sarkomresektion – Überleben, Funktion, Lebensqualität | Kolbenschlag, J. (Bochum) Routine nutritional evaluation and subsequent initiation of a case and finding adapted nutritional therapy in the clinical-surgical daily – “Standard Operating Procedure” (SOP) | Meissner, C. (Magdeburg) ID: 557 Knapp oder weit? Welcher Sicherheitsabstand sollte bei Weichgewebssarkomen erzielt werden? | Kolbenschlag, J. (Bochum) ID: 534 Corneale confokale Mikroskopie in der Frühdiagnostik Chemotherapieinduzierter Neuropathie (CIN) – eine Pilotstudie | Reinacher-Schick, A. (Bochum) Donnerstag, 25. Februar 2016 Topic: Supportive Care ID: 46 The relevance of nutritional treatment in cancer therapy | Heckel, M. (Thalmässing) ID: 107 Patient satisfaction during treatment with Sancuso for CINV 12:45 – 14:15 Uhr Topic: Breast Cancer ID: 34 Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade | Ignatov, A. (Magdeburg) Evaluation of a multiprofessional cancer care model as contribution to patient safety | Jansen, C. (Bonn) ID: 40 Prognosis of breast cancer subtypes in routine clinical care ID: 174 OncoBOS: Biosimilar epoetin alfa in patients with chemotherapy induced anaemia – first analysis from a non-interventional German cohort study ID: 65 Real-time long-term detection of circulating breast cancer cells induced by medical interventions | Juratli, M. (Frankfurt/M.) Bulenda, D. (Holzkirchen) ID: 83 ID: 243 Primary prophylaxis of febrile neutropenia in female patients receiving dose-dense biweekly chemotherapy in the clinical routine using long-acting granulocyte colony-stimulating factors is safe and effective Recurrence and survival of breast cancer patients depending on intrinsic subtypes defined by surrogate parameters – a population-based analysis ID: 84 Probability of metastatic disease at primary diagnosis according to different intrinsic subtypes defined by surrogate parameters – a population-based analysis of breast cancer patients | Schrodi, S. (München) ID: 91 Prognostic impact of interferon regulating factor 4 (IRF4) in node-negative breast cancer | Heimes, A. (Mainz) ID: 97 Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity ID: 118 Breast cancer and therapy in migrating and native women in Germany: is there a difference? | von Au, A. (Heidelberg) ID: 129 Evaluation of Option Grids to support shared decision-making in breast cancer treatment | Scholl, I. (Hamburg) ID: 130 The DETECT study concept – metastatic breast cancer and circulating tumor cells | Schramm, A. (Ulm) ID: 131 Factors predicting discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer ID: 135 Komplementärmedizin in der niedergelassenen Praxis | Rotmann, A. (Rodgau) Maessen, D. (Düsseldorf) ID: 171 Kurbacher, C. (Bonn) ID: 255 The effect of a chemotherapy accompanying 4-week aerobic endurance exercise intervention on incidence and severity of cancer related cognitive impairments in leukemia patients. A randomized controlled trial. Oberste, M. (Köln) ID: 268 Internet as an appropriate medium for training support in cancer patients. A systematic review of the literature | Pfirrmann, D. (Mainz) ID: 323 Influence of a single exercise session on natural killer cell cytotoxicity and tumor infiltration in preoperative esophageal carcinoma patients – a study protocol | Schenk, A. (Köln) ID: 402 Comparing different supportive measures – how cancer patients profit from exercise and stress management | Wiskemann, J. (Heidelberg) ID: 513 Thromboembolic events in hematological/oncological patients: diagnosis, treatment patterns and adherence to treatment guidelines in clinical practice Ostermann, H. (München) ID: 515 Analysis concerning responsibility for rehabilitation sports in oncology throughout Germany on federal state level | Giesen, A. (Köln) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 Hennigs, A. (Heidelberg) Schrodi, S. (München) Brockhoff, G. (Regensburg) Janni, W. (Ulm) 199 ID: 154 Disseminated tumor cells in luminal breast cancer: prognosis and treatment ID: 360 eHealth acceptance in breast cancer care | Schindler, F. (München) Stefanovic, S. (Heidelberg) ID: 370 Cognitive function in relation to Aromatase inhibitors among breast cancer survivors | Fersis, N. (Bayreuth) ID: 379 Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase-II-trial | Liedtke, C. (Lübeck) ID: 383 Validation of a BRCAness test to select for targeted therapies in triplenegative breast cancer | Groß, E. (München) ID: 396 Compelling evidence for FANCM as a breast cancer susceptibility gene ID: 416 TREAT CTC: an innovative therapy approach to eliminate circulating tumor cells (CTCs) | Tzschaschel, M. (München) ID: 441 Characterization of circulating tumor cells regarding mutational status of PIK3CA and expression of androgen receptor | Meier-Stiegen, F. (Düsseldorf) ID: 173 Young breast cancer survivors – reproductive concerns, life satisfaction and cancer-specific distress | Burgmann, M. (München) ID: 189 Detection of EpCAM-negative circulating tumor cells in metastatic breast cancer patients by using VyCAP filters technology | Lampignano, R. (Düsseldorf) ID: 202 Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland Holleczek, B. (Saarbrücken) ID: 225 ID: 230 WSG BCIST study: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC) | Würstlein, R. (München) Analysis of prognostication and treatment benefit tools for women with early breast cancer as a prerequisite for informed shared decision making Mühlbauer, V. (Hamburg) Neidhardt, G. (Köln) ID: 234 Phototheranostics immunoconjugates to detect eliminate triple negative breast cancer cells | Hussain, A. (Aachen) ID: 496 ID: 236 Brain metastases in Breast Cancer Network Germany (BMBC, GBG 79): the introduction of the multicenter register and analysis of patient data HER2 testing in neoadjuvant breast cancer trials – improved concordance of HER2 status in different pathology laboratories | Pfitzner, B. (Berlin) ID: 511 Comparison of tumor cell dissemination into the blood and bone marrow in patients with primary breast cancer | Hartkopf, A. (Tübingen) ID: 248 β-hydroxybutyrate inhibits growth of breast cancer cell lines ID: 520 Eribulin 1,23 mg/m² an d1/8 q3w als Therapieoption beim fortgeschrittenen metastasierten Mammakarzinom in der klinischen Anwendung ID: 531 Treatment with Eribulin Mesylate infl uences expression of genes known to induce malignant transformation in triple-negative breast cancer cell lines in vitro | Bräutigam, K. (Lübeck) ID: 536 Use of BSP II and HER2 as markers of breast cancer metastasis ID: 548 5-year survival of young mothers with breast cancer | Waldmann, A. (Lübeck) ID: 560 GAIN2: Adjuvant phase-III-trial comparing an intensifi ed dose-dense (idd) adjuvant therapy with EnPC compared to a dose-dense (dd), dose-adapted therapy with dtEC-dtD in patients with primary high-risk breast cancer: results of the second safety interim a | Loibl, S. (Neu-Isenburg) ID: 561 nab-Paclitaxel at a dose of 125 mg/m² weekly is more efficacious but less toxic than at 150 mg/m². Results from the neoadjuvant randomized GeparSepto study (GBG 69) | Loibl, S. (Neu-Isenburg) ID: 562 Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body mass index – results of the prospectively randomized GAIN study. | Loibl, S. (Neu-Isenburg) I Laakmann, E. (Hamburg) Bartmann, C. (Würzburg) ID: 271 Prototypical implementation of an expert system supporting medical documentation and clinical decision | Andrzejewski, D. (Flensburg) ID: 279 EpCAM-independent enrichment of circulating tumor cells (CTCs) in metastatic breast cancer | Schneck, H. (Düsseldorf) ID: 294 Life satisfaction and life quality in the elderly patient with breast cancer Wuerstlein, R. (München) ID: 295 Possible role of estrogen receptor-alpha in the signaling mechanism of progesterone receptor membrane component-1 in human breast cancer ID: 296 Isolation and characterization of tumor infiltrating lymphocytes in primary human breast cancer | Ugocsai, P. (Regensburg) ID: 303 Frequent expression of PDL-1 on circulating epithelial tumor cells (CETCs) could be a new therapeutic target in breast cancer patients ID: 351 In vitro cultivation of circulating tumor cells of metastatic breast cancer patients | Franken, A. (Düsseldorf) ID: 358 TruRisk®-based next-generation sequencing reveals a high prevalence of deleterious ATM mutations in BRCA1/2-negative breast and ovarian cancer families | Heimbach, A. (Köln) ID: 359 Ten years of mammography screening in North Rhine-Westphalia: analysis of impact indicators | Heidrich, J. (Münster) Benndorf, D. (Homburg/S.) Widulle, D. (Heidelberg) Neubauer, H. (Düsseldorf) Pizon, M. (Bayreuth) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 201 Topic: Developmental Therapeutics/Immunotherapy/Cellular Theraphy Topic: Gynecologic Cancer ID: 49 ID: 33 Survival advantage of lymphadenectomy in endometrial cancer – data from Sachsen-Anhalt registry on 1502 patients with median follow-up of 78 months | Ignatov, A. (Magdeburg) Frentsch, M. (Berlin) ID: 41 Improvement in efficacy of Cetuximab, Panitumumab, Trastuzumab and Rituximab by dianthin conjugation and co-application of SO1861 Fertility-sparing surgery (FSS) in patients with borderline ovarian tumors (BOT) | Vdovichenko, N. (Essen) ID: 76 Prognostic impact of conventional tumor grade in surgically treated FIGO stage IB to IIB squamous cell cervical cancer | Horn, L. (Leipzig) Immunomodulatory impacts of the novel HDAC inhibitor Resminostat Prenzel, T. (Planegg-Martinsried) ID: 69 ID: 212 CD40L: a new decisive antitumor effector function of CD8+ T cells Panjideh, H. (Berlin) ID: 331 Generation of new DNA- and protein vaccines for active immunotherapy against MYCN-expressing neuroblastoma | Zumpe, M. (Greifswald) ID: 77 ID: 335 Generation and characterization of a new chimeric human/mouse antiIdiotype antibody ganglidiximab for active immunotherapy against neuroblastoma | | Eger, C. (Greifswald) Prognostic impact of tumor size using a cut-off value of 2 cm in surgically treated FIGO stage IB cervical cancer | Horn, L. (Leipzig) ID: 78 Peritumorale Entzündung beim Zervixkarzinom – prognoserelevant ?? ID: 80 KRAS and BRAF mutational analyses indicate monoclonal origin of peritoneal implants and lymph node deposits in serous borderline ovarian tumors (s-BOT) | Horn, L. (Leipzig) ID: 106 Trends in surgery of squamous cell vulvar cancer patients over a 16-year period (1998-2013): a population-based analysis | Rottmann, M. (München) ID: 127 Prognostic and predictive values of primary vs secondary platinum resistance for Bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial | Trillsch, F. (Hamburg, Germany) ID: 167 Human papillomavirus (HPV) vaccinated and still dysplasia ID: 437 Colitis as an immune-mediated side effect of Ipilimumab treatment?! ID: 440 “Small potpourri” of an immune-mediated side effect of Ipilimumab treatment of metastatic melanoma with difficult diagnostic challenge Horn, L. (Leipzig) Unger, S. (Greifswald) Torz, M. (Greifswald) Topic: Epidemiology ID: 88 Subsequent malignancies among survivors of multiple myeloma in Germany: cancer registry data-based analysis (1990-2011) | Baras, N. (Berlin) ID: 165 Objections to be registered at the cancer registry of Baden-Württemberg ID: 182 German and American lymphoma study and cancer registry data – comparison of subtypes | Friedrich, S. (Heidelberg) ID: 330 Reporting of colorectal cancer (ICD-10 C18-C21): decline in colorectal cancer incidence does not apply to temporal anal cancer trends in Germany Hahlbohm, U. (Hameln) ID: 172 Retrospective analysis of compliance, compatibility and quality of life of gynecological cancer patients under complementary treatment ID: 184 Biomarker results from PENELOPE, a randomised phase-III-trial evaluating chemotherapy (CT) ± Pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression | Marmé, F. (Heidelberg) ID: 192 The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node | Prieske, K. (Hamburg) ID: 193 Analytical validation of a CE marked companion diagnostic tumor test to detect BRCA1 and BRCA2 mutations in ovarian cancer for clinical use Hermann, S. (Heidelberg) Buttmann-Schweiger, N. (Berlin) ID: 334 “Cancer in Germany“ 2013 – current epidemiological cancer statistics Bertz, J. (Berlin) ID: 338 Trends of advanced breast cancer incidence rates after implementation of the mammography screening program in the Regierungsbezirk (RB) Münster Simbrich, A. (Münster) ID: 347 ID: 409 Papillary type mostly accounts for rise in incidence rates of thyroid cancer in Germany | Schönfeld, I. (Berlin) How plausible is the causes of death statistics in cancers? | Belova, I. (Greifswald) Wagner, A. (München) Wehnelt, S. (München) ID: 194 C-met is overexpressed in type I ovarian cancer – results of an explorative analysis in a cohort of consecutive ovarian cancer patients ID: 198 Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer | Kuhlmann, J. (1307) ID: 200 Trends in prognostic factors and treatment of invasive cervical cancer patients over a 16-year period (1998-2013): a population-based analysis Battista, M. (Mainz) Rottmann, M. (München) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 203 ID: 224 Distribution pattern of node metastases in advanced ovarian cancer ID: 539 The impact of age on comorbidity, toxicity of chemotherapy and survival in recurrent ovarian cancer patients | Woopen, H. (Berlin) ID: 545 Laparoskopische Corpus-und Cervixcarcinom-OPs: Erfahrungen eines universitären Zentrums | Mavrova, R. (Homburg) ID: 551 A simple and precise test towards prevention on HPV-induced cancers via direct detection of the viral E6 oncoprotein | Schweizer, J. (Fremont, CA) ID Bachmann, C. (Tübingen) ID: 239 Influence of educational videos or information sheets on the levels of knowledge and anxiety of patients consulting for cervical dysplasia Schüler-Toprak, S. (Regensburg) ID: 241 Salvage chemotherapy for heavily pretreated ovarian carcinoma or related malignancies: high activity of oral Treosulfan combined with prolonged lowdose infusional Gemcitabine is equal in both platinum-resistant and potentially platinum-sensitive disease | Kurbacher, C. (Bonn) ID: 256 Lifestyle changes in patients following the diagnosis of breast- and/or gynecologic carcinoma | Wiedeck, C. (München) ID: 306 Chemotherapy (CT) ± Pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebocontrolled randomized phase-3-trial | Mahner, S. (München) ID: 343 Identifi cation of differentially activated signal transduction pathways in platinum-resistant ovarian cancer | Naskou, J. (Düsseldorf) ID: 447 Robot-assisted surgery in morbidly obese patients with endometrial cancer Kurzeder, C. (Essen) ID: 452 Management of recurrent and metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006 | Battista, M. (Mainz) ID: 455 Comparison of Delphi Screener and Evalyn Brush self-samplers for HPV screening in low resource settings (accessing*) | Krings, A. (Berlin) ID: 457 SPECT/CT for preoperative SLN detection in vuvlar cancer: improved detection and anatomical localization of SLN by three-dimensional visualization | Klapdor, R. (Hannover) ID: 471 Primary diffuse large B-cell lymphoma with manifestation in uterus: cases duplicity in gynecological oncology 2015 | Barinoff, J. (Frankfurt/M.) ID: 481 Experiences with off-lable use of Bevacizumab in patients with first-diagnosed locally advanced and metastatic cervical cancer | Wirtz, M. (Cologne) ID: 505 A new tool for detection of HPV E7 proteins in cervical samples Koch, I. (Neuried) ID: 507 HER2/neu score as a prognostic factor for outcome in patients with triple negative breast cancer | Schmidt, G. (Homburg) ID: 509 A unique assay for verification of cervical cancer tests targeting specific cytoskeletal biomarkers| Koch, I. (Neuried) ID: 519 Langzeitanwendung von Eribulin 1,23 mg/m² und 1/8 q3w beim stark vorbehandelten und fortgeschritten metastasierten Mammakarzinom – ein Fallbericht | Benndorf, D. (Homburg) ID: 522 Functionality of the tumor suppressor microRNA-1 in ovarian cancer progression | Stope, M. (Greifswald) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 Topic: Head and Neck Cancer ID: 23 Improvement in survival in patients with oral squamous cell carcinoma ID: 58 The value of the HPV status and its detection methods in oral and oropharyngeal squamous cell carcinomas – a meta-analysis | Götz, C. (München) ID: 63 The oral cancer awareness campaign in Schleswig-Holstein: conceptual background and design to increase early detection of oral cancer ID: 64 In vivo detection of circulating tumor cells during tumor manipulation Kreppel, M. (Köln) Hertrampf, K. (Kiel) Juratli, M. (Frankfurt/M.) ID: 95 Ibuprofen and diclofenac restrict migration and proliferation of human glioma cell lines in vitro | Leidgens, V. (Regensburg) ID: 96 Isolation and characterization of human brain tumour initiating cells leading invasion in an in situ migration model | Leidgens, V. (Regensburg) ID: 102 Invasive head and neck cancer – data of a population-based clinical cancer registry | Schlesinger-Raab, A. (München) ID: 124 Deeskalationsstrategie beim Oropharynxkarzinom – Risikostratifikation an einer prospektiv erfassten, primär chirurgisch therapierten Kohorte Wittekindt, C. (Giessen) ID: 139 Changes in macrophage polarization between diagnostic biopsy and tumor resection in oral squamous cell carcinomas | Weber, M. (Erlangen) ID: 146 Association of macrophage polarization with tumor outcome in early stage oral squamous cell carcinomas | Wehrhan, F. (Erlangen) ID: 185 Glukosestoffwechsel und Aggressivität des Mundhöhlenkarzinoms Eckert, A. (Halle/S.) ID: 186 Adenoid-zystisches Karzinom des Oberkiefers | Eckert, A. (Halle/S.) ID: 206 Molekulare Parameter zur Rezidivkalkulation beim Plattenepithelkarzinom der Mundhöhle | Kappler, M. (Halle(S)) ID: 214 Effect of Sorafenib on Cisplatin-based radiochemotherapy in head and neck cancer cells | Möckelmann, N. (Hamburg) ID: 216 Identification of functional proteomic signatures in HPV positive head and neck cancer | Petersen, H. (Hamburg) 205 Treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) acoording to the EXTREME protocol in daily routine. Survival outcomes compared to the EXTREME study results and conventional chemotherapy. | | Münscher, A. (Hamburg) Topic: Molecular Pathology ID: 219 Importance of nodal yield in neck dissection: indicator of surgical and oncological quality | Bier, J. (Hamburg) ID: 460 ID: 235 Feasibility and results of radiotherapy (RT) or chemoradiation (RCT) for unselected elderly patients with squamous cell carcinoma of the head and neck (SCCHN) – a retrospective monoinstitutional study Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment | Budczies, J. (Berlin) ID: 468 Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer | Sers, C. (Berlin) Hautmann, M. (Regensburg) ID: 558 Molecular genetic analysis of primary CNS lymphoma (PCNSL) | Radke, J. (Berlin) Vitamin D3 serum level influences lymphogenic metastasization as well as natural killer cell-mediated cytotoxicity in patients with head and neck squamous cell carcinoma | Bochen, F. (Homburg) Topic: Pflegerische Beiträge ID: 217 ID: 245 ID: 313 Identification of prognostic and predictive biomarkers in malignant pleural mesothelioma in 134 patients from two research sites (Berlin and Essen) Mairinger, F. (Berlin) ID: 259 Two-year survival analysis of fifty consecutive head and neck squamous cell carcinoma patients treated primarily with transoral robotic surgery (TORS) in a single European academic centre | Lörincz, B. (Hamburg) ID: 187 Staff retention and job satisfaction of non-medical personnel in oncology practices | Osburg, S. (Köln) ID: 136 Therapiebegleitendes Patientenhandbuch | Ludwig, N. (Heidelberg) ID: 362 Erufosine causes cell cycle downregulation in head and neck cancer ID: 344 Individualisierte Onkologie durch Digitalisierung – smart and safe! Ansari, S. (Heidelberg) ID: 378 Chemosensitivity of HPV-positive and HPV-negative HNSCC cell lines Rieckmann, T. (Hamburg) ID: 381 Radiosensitization of HPV-positive HNSCC cells through the inhibition of Chk1 and Wee1 | Rieckmann, T. (Hamburg) ID: 382 Characterization of tumor-associated blymphocytes in head and neck squamous cell carcinoma | Lechner, A. (Köln) ID: 432 Laboratory values as prognostic factors for the outcome of concurrent radiochemotherapy in the treatment of locally advanced head and neck cancers: secondary results of two European randomized phase-III-trials (ARO 95-06, SAKK 10/94) | Ghadjar, P. (Berlin) ID: 449 Evaluation of hyperspectral imaging in early recognition of precancerous and cancerous lesions in mouth and oropharynx | Laffers, W. (Bonn) ID: 494 Influence of microRNA profi les and immune signatures on the effi cacy of radiochemotherapy in locally advanced head and neck squamous cell carcinoma | Heß, A. (Berlin) ID: 538 Multimodale Therapie bei immunsupprimierten Patienten nach Organtransplantation mit fortgeschrittenem HNSCC des UICC-Stadiums IV – was ist möglich? Eine Fallbeschreibung | Schedler, M. (Ramstein) ID: 567 TCF-21-Hypermethylierung in Plattenepithelkarzinomen des Nasenvestibulums | Koopmann, M. (Münster) ID: 568 Die Bedeutung von Nodal Yield bei der Neck Dissection: Chirurgischer und onkologischer Qualitätsindikator | Bier, J. (Hamburg) Elmer, A. (Berlin) ID: 451 Parastomale Hautveränderungen unter zielgerichteter Antikörpertherapie in der Onkologie – eine neue Ursache für parastomale Komplikationen und deren pflegerischen Versorgungsschwierigkeiten? | Gruber, G. (München) ID: 544 „Die Übelkeit hat mir meine Grenzen aufgezeigt“ – Erfahrung, Umgang und Auswirkungen von Übelkeit bei Erwachsenen, die sich zuhause nach ambulant verabreichten emetogenen Chemotherapien selbst versorgen: Eine qualitative Studie | Mößner, U. (Gutach) Topic: Radiation ID: 51 Establishing high precision radiotherapy with flattening-filter-free techniques in clinical routine – initial experiences in a single institution ID: 297 Effective long-term local results and prognostic factors after fractionated stereotactic radiotherapy of 257 intracranial meningeoma Rieber, J. (Heidelberg) Lubgan, D. (Erlangen) ID: 372 The radiotherapy of glioblastoma might be enhanced by the addition of chloroquine prior to irradiation. | Bühler, H. (Herne) ID: 377 Motility as well as clonogenic survival of breast cancer and glioblastoma cells is reduced by hyperthermia alone or in combination with irradiation. ID: 466 Radiotherapy, bisphosphonates and surgical stabilization of complete or impending pathologic fractures in patients with metastatic bone disease Bühler, H. (Herne) Fakhrian, K. (Herne) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 207 ID: 467 Genital sparing with vaginal dilator for pelvic radiotherapy for female patients | Fakhrian, K. (Wroclaw, Poland) ID: 491 The therapeutic effect of photon irradiation on viable glioblastoma cells is reinforced by hyperbaric oxygen. | Bühler, H. (Herne) ID: 543 Proton beam irradiation for uveal melanoma | Joussen, A. (Berlin) Freitag, 26. Februar 2016 12:45 – 14:15 Uhr Topic: Cancer Prevention ID: 178 Temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine ID: 218 Robo1-expression decreases the motility of irradiated glioma cells in vitro ID: 240 Long-term outcome and prognostic factors of radiation therapy for low-grade gliomas | Rieken, S. (Heidelberg) ID: 270 Assessment of the use of complementary therapy in a cohort of Swiss glioma patients | Eisele, G. (Zurich) ID: 309 Be smart against cancer – a school-based program promoting cancer awareness | Stölzel, F. (Dresden) ID: 364 Feasibility assessment on a lifestyle intervention in healthy and diseased BRCA 1/2 mutation carriers | Dukatz, R. (München) Stritzelberger, J. (Erlangen) Topic: Skin Cancer including Melanoma ID: 54 ID: 117 Comparison of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in total scalp irradiation (TSI) of extensive skin maligancies of the scalp | Ostheimer, C. (Halle) Pembrolizumab in an advanced melanoma and immune suppressed patient with a Churg-Strauss syndrome following Ipilimumab-induced colitis Nguemgo Kouam, P. (Herne) Maul, L. (Kiel) ID: 350 Metastatic melanoma in pregnancy – a diagnostic and therapeutic challenge Pföhler, C. (Homburg/Saar) ID: 398 Difficult treatment of cutaneous T-cell lymphoma with a haematological malignancy in medical history | Ahmed, M. (Greifswald) ID: 434 Benchmarking of the DKG check list for inclusion criteria of BRCA testing ID: 399 Atypical Fibroxanthoma (AFX) – a sarcoma or a Spindle cell carcinoma (SpCC)?? | Kaisermayer, E. (Greifswald) ID: 506 DNA repair in the defense against alkylation-induced colorectal carcinogenesis | Kaina, B. (Mainz) ID: 433 Challenges in treating in transit melanoma metastases and development of new approaches. | PEDIADITI, P. (Greifswald) ID: 319 Role of valproic acid or levetiracetam in survival of glioblastoma patients ID: 472 HDAC1/HDAC2/HDAC3 mediated RAD51 and FANCD2 expression contribute to the resistance of melanoma cells to alkylating chemotherapeutics ID: 395 Is a modification of the radiotherapeutic target volume necessary after resection of glioblastomas with opening of the ventricles? Rhiem, K. (Köln) Happold, C. (Zurich) Adeberg, S. (Heidelberg) Roos, W. (Mainz) ID: 495 The nerve growth factor receptor CD271 is crucial for stem-like properties of melanoma cells and determines drug response | Redmer, T. (Berlin) ID: 537 PD-1 blockade in nonmelanoma skin cancer | Winkler, J. (Heidelberg) ID: 550 LDC-3 and PTPIP51 a winning team! | Chehab, R. (Gießen) 32. Deutscher Krebskongress 24.– 27. Februar 2016 #dkk2016 ID: 401 Are there correlations between clinical patient data and molecular expression profiles of the key RTK/MAP kinase & AKT/mTOR signaling pathways in human meningiomas? | Walter, J. (Jena) ID: 406 FGFR1 seems to be a key regulator of pluripotency and/or differentiation in meningiomas | Walter, J. (Jena) ID: 442 Congenital deafness leading to the diagnosis of “atypical teratoid/rhabdoid tumor (AT/RT)“ | Fasold, J. (Rostock) ID: 445 Anaplastic meningiomas WHO grade III lack of somatic AKT1-mutations and show an overexpression of EGF-receptor | Juratli, T. (Dresden) 209